Response to SARS-CoV-2 (COVID-19) vaccines in patients receiving B-cell modulating antibodies for renal immune disease

Response to SARS-CoV-2 (COVID-19) vaccines in patients receiving B-cell modulating antibodies for renal immune disease - RENCOVAC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027049

Enrollment

121

Registered

2021-10-29

Start date

2021-09-28

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: Patients recieving Rituximab for autoimmune kidney disease and completes SARS-CoV-2 base-immunisation.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Age > 18 years - Diagnosis of renal immunological disease - Previous or ongoing antibody treatment with Rituximab - Full vaccination with either mRNA-based (BNT162b2, mRNA-1273), or Vector-based (ChAdOx1, Ad26.COV2.S) SARS-CoV-2 vaccines

Exclusion criteria

Exclusion criteria: Previous COVID-19-disease, use of antimetabolite drugs, such as Mycophenolate Mofetil, Azathioprine, Methotrexate two months prior to vaccination.

Design outcomes

Primary

Measure	Time frame
Humoral and cellular vaccination response in patients receiving Rituximab therapy, evaluated by quantification of SARS-CoV-2-IgG2 and IFN-g-release in patient blood, measured between one and 21 weeks after completed base immunisation.	—

Countries

Germany

Contacts

Public ContactThomas Welte

Universitätsklinikum Freiburg, Medizinische Klinik IV

thomas.welte@uniklinik-freiburg.de0049-761-270-33470

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 11, 2026